This study employs a multi-faceted strategy integrating serum-urine pharmacochemistry, network pharmacology, metabolomics, and pharmacological experiments to characterise AR’s in vivo active components and elucidate its anti-T2DM mechanisms. Here, AR is linked to type 2 diabetes mellitus.